SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. is surging due to extreme volatility and high interest in its low-float structure, as traders pivot toward energy stocks amid renewed geopolitical tensions and supply disruptions in the Middle East. The community is actively debating the stock's squeeze potential while focusing on the broader, long-term thesis regarding Europe's urgent need for domestic natural gas reserves.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending as investors weigh aggressive M&A expansion plans led by CEO Brad Jacobs against recent volatility, with community debate centered on whether to treat current price weakness as a long-term accumulation opportunity or a signal of overvaluation. The stock remains a focal point for discussion around its role in the building materials sector, with participants closely monitoring for the next acquisition announcement to provide renewed momentum.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

United Airlines is navigating significant volatility as the industry grapples with an unprecedented government shutdown that has triggered FAA-mandated flight capacity cuts and severe air traffic controller staffing shortages. Investors are intensely debating whether the airline's premium loyalty model provides a durable margin cushion or if the escalating operational disruptions and fuel price pressures from broader Middle East instability will weigh on upcoming performance.

Forum Energy Technologies, Inc. designs, manufactures, and distributes products to the oil and natural gas industry. It operates through the Drilling and Completions and Artificial Lift and Downhole segments. The Drilling and Completions segment designs, manufactures and supplies products and solutions to the drilling, subsea, coiled tubing, well stimulation and intervention markets, including applications in oil and natural gas, renewable energy, defense and communications. The Artificial Lift and Downhole segment designs, manufactures and supplies products and solutions for the artificial lift, production and infrastructure markets. The company was founded in 2005 and is headquartered in Houston, TX.

Forum Energy Technologies Inc

Forum Energy Technologies is attracting investor attention as its recent Variperm acquisition and deleveraging efforts signal a shift toward stronger free cash flow and potential share repurchases. The community is actively discussing the stock's valuation disconnect and its positioning as a key beneficiary of resilient international activity and rebounding natural gas drilling demand.

T1 Energy, Inc. engages in developing battery solutions. It focuses on energy storage systems and commercial mobility. The company was founded by Tom Einar Jensen, Peter Matrai, and Tore Ivar Slettemoen on August 31, 2023 and is headquartered in Austin, TX.

T1 Energy Inc.

T1 Energy is experiencing significant volatility driven by the recent release of a negative short report and investor reactions to a large block share sale. Despite the pressure, the community remains heavily focused on the company's long-term potential as a domestic solar manufacturer, closely monitoring institutional buy-ins and expectations for upcoming earnings and offtake agreements.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Clene Inc. is trending as investors await critical updates following recent FDA interactions, with the community closely tracking potential news regarding the accelerated approval pathway for its lead ALS candidate, CNM-Au8. Discussions are heavily focused on the anticipation of new biomarker data and potential NDA submission updates, which shareholders view as primary catalysts for a significant valuation rerating.

Green Thumb Industries, Inc. engages in the manufacture and distribution of branded cannabis products. Its brands include RYTHM, Dogwalkers, Beboe, Good Green, Doctor Solomon’s, and &Shine. It operates through the Retail and Consumer Packaged Goods segments. The Retail segment focuses on retailing cannabis to patients and consumers. The Consumer Packaged Goods segment refers to the cultivation, production, and sale of cannabis products to retail stores. The company was founded by Benjamin Kovler and Max Cohen on February 18, 2002 and is headquartered in Chicago, IL.

Green Thumb Industries Inc - Ordinary Shares (Sub Voting)

Green Thumb Industries

Green Thumb Industries is trending as investors weigh potential federal regulatory shifts alongside a notable surge in beverage segment revenue, which some analysts believe could scale exponentially by the next decade. The community remains focused on the long-term impact of rescheduling and institutional accumulation, with many shareholders emphasizing patience as they navigate short-term price volatility and sector-wide regulatory developments.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is capturing significant community attention as investors debate its potential for a major breakout, with many highlighting its resilience and year-to-date performance relative to other leading cryptocurrencies. The sentiment remains polarized, with bullish traders pointing toward upcoming network upgrades and whale accumulation, while skeptics express frustration over stagnant price action and compare the asset to other market alternatives.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is experiencing significant volatility as the market reacts to intense geopolitical instability in the Middle East, specifically regarding energy infrastructure and the potential closure of the Strait of Hormuz. Community discussion is sharply divided between bulls betting on a massive supply-driven price spike due to infrastructure damage, and bears highlighting the leveraged decay inherent in the product alongside bearish seasonal demand factors.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing heightened community discussion surrounding the highly anticipated Goliath mainnet launch and potential enterprise-grade infrastructure developments. Investors are actively debating the token's long-term utility versus its history of volatility, with many monitoring for a sustained breakout while others caution against what they perceive as repetitive pump-and-dump market cycles.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tenaya Therapeutics (NASDAQ:TNYA) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen cut shares of Tenaya Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Chardan Capital Reiterates Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA)

Chardan Capital reiterated a "buy" rating and set a $8.00 price target on shares of Tenaya Therapeutics in a research report on Thursday...

Tenaya Therapeutics (NASDAQ:TNYA) Issues Earnings Results, Meets Expectations

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) released its earnings results on Wednesday. The company reported ($0.12) earnings per share for the quarter, hitting analysts' consensus estimates...

Lifesci Capital Upgrades Tenaya Therapeutics (NASDAQ:TNYA) to Strong-Buy

Lifesci Capital raised shares of Tenaya Therapeutics to a "strong-buy" rating in a report on Thursday...

<ul class="summary-bullets"><li>Under the deal, Tenaya Therapeutics will validate up to 15 gene targets and receive as much as $1.13 billion in development and commercial milestone payments from Alnylam.</li><li>Alnylam will be responsible for all development and commercialization activities of therapeutics associated with the identified gene targets, the companies said.</li></ul> Shares of Tenaya Therapeutics, Inc. (TNYA) pulled back after hours after a significant rally during the regular session on Thursday after the company said that it has entered into a research collaboration deal with Alnylam Pharmaceuticals (ALNY) to potentially develop drugs for cardiovascular disease.TNYA shares pulled back 5% in extended hours of trading after closing up 41% in the regular session.<h2 class="st-heading-2">Deal For Heart Drugs</h2>Under the deal, Tenaya Therapeutics will validate up to 15 gene targets and receive as much as $1.13 billion in development and commercial milestone payments from Alnylam if all the targets lead to approved therapies for cardiovascular disease. Tenaya will receive up to $10 million in the form of an upfront payment, the company said.“By combining our modality agnostic target identification and validation capabilities with Alnylam’s leadership in RNA interference therapeutics, we have an opportunity to advance candidates for novel genetic targets with the potential to create transformational medicines for patients with heart disease,” Tenaya CEO Faraz Ali said.Alnylam will be responsible for all development and commercialization activities of therapeutics associated with the identified gene targets, the companies said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TNYA stock rose from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.A Stocktwits user said that they are awaiting positive data for Tenaya’s TN401 this year with “no curative competition.” TN-401 is a gene therapy for a heart condition called PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).<stembedurl>https://www.stocktwits.com/Raumerica/message/646689743</stembedurl>Another said that the best part about the deal is that Tenaya will just be researching fifteen additional targets for future commercialisation while still owning all of its own drugs.<stembedurl>https://www.stocktwits.com/Raumerica/message/646703938</stembedurl><a href="https://stocktwits.com/symbol/TNYA">TNYA stock</a> has gained 78% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/owlet-stock-is-down-26-percent-after-hours-after-it-reports-q4-2025-earnings/cZdX4n1RI36">Owlet Stock Is Down 26% After Hours – How Did The Company’s Q4 Results Fare?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

TNYA Pulls Back After Hours Following Significant $1.13B Deal-Spurred Rally

Tenaya shares closed 40% higher in the regular trading session after it entered into a research collaboration deal with Alnylam Pharmaceuticals. 

Equity

Tenaya shares closed 40% higher in the regular trading session after it entered into a research collaboration deal with Alnylam Pharmaceuticals. 


Tenaya Therapeutics Stock Jumps After New Alnylam Deal

Tenaya Therapeutics stock jumps after announcing a research collaboration with Alnylam worth up to $1.13 billion in milestone payments.read more...

Tenaya Therapeutics (TNYA) Projected to Post Earnings on Monday

Tenaya Therapeutics (NASDAQ:TNYA) will be releasing its Q4 2025 earnings before the market opens on Monday, March 9. (View Earnings Report at...

Tenaya Therapeutics (NASDAQ:TNYA) Major Shareholder Group Gp Lp Column III Sells 658,440 Shares

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) major shareholder Group Gp Lp Column III sold 658,440 shares of the company's stock in a transaction on Tuesday, February 24th. The stock was...

Insider Selling: Tenaya Therapeutics (NASDAQ:TNYA) Major Shareholder Sells 658,440 Shares of Stock

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) major shareholder Group Gp Lp Column III sold 658,440 shares of the company's stock in a transaction dated Tuesday, February 24th. The stock...

Group Gp Lp Column III Sells 3,511,826 Shares of Tenaya Therapeutics (NASDAQ:TNYA) Stock

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) major shareholder Group Gp Lp Column III sold 3,511,826 shares of the stock in a transaction on Wednesday, February 25th. The shares were...

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. Its programs include TN-201, TN-401, and TN-301. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Newell Olson in 2016 and is headquartered in South San Francisco, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.09	--	--	N/A
Q4 '25	-$0.12	-$0.12	0.91%	BEAT
Q3 '25	-$0.15	-$0.12	19.05%	BEAT
Q2 '25	-$0.19	-$0.14	25.88%	BEAT
Q1 '25	-$0.19	-$0.24	-26.32%	MISSED

TNYA
Tenaya Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest TNYA News

TNYATenaya Therapeutics Inc